curasan AG: Novel bone regeneration material approved for sale in Europe
30-Mar-2011
- Germany
“With Osseolive® emerging from our well-stocked development pipeline, we now have an ideal extension to our tricalcium-phosphate products”, stated Hans Dieter Rössler, CEO. Osseolive® has been specifically designed for the treatment of large defects in combination with bone growth supporting substances, such as bone marrow aspirate, stem cells, and bone morphogenetic proteins (BMPs).”
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.